Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.
A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.
Dibenzothiazepines are a class of heterocyclic chemical compounds that contain a dibenzothiazepine ring structure, which have been used in the development of various pharmaceutical drugs, particularly as tranquilizers, muscle relaxants, and anticonvulsants, but their use has declined due to side effects and the development of newer drugs.
A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
A group of two-ring heterocyclic compounds consisting of a benzene ring fused to a diazepine ring.
A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
Compounds containing phenyl-1-butanone.
Benzopyrroles with the nitrogen at the number two carbon, in contrast to INDOLES which have the nitrogen adjacent to the six-membered ring.
A subfamily of G-PROTEIN-COUPLED RECEPTORS that bind the neurotransmitter DOPAMINE and modulate its effects. D2-class receptor genes contain INTRONS, and the receptors inhibit ADENYLYL CYCLASES.
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.
An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
A substituted benzamide that has antipsychotic properties. It is a dopamine D2 receptor (see RECEPTORS, DOPAMINE D2) antagonist.
Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)
A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.
Piperazines are a class of heterocyclic organic compounds containing a seven-membered ring with two nitrogen atoms at positions 1 and 4, often used in pharmaceuticals as smooth muscle relaxants, antipsychotics, antidepressants, and antihistamines, but can also be found as recreational drugs with stimulant and entactogen properties.
A subtype of dopamine D2 receptors that are highly expressed in the LIMBIC SYSTEM of the brain.
Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells.
Drugs that bind to and activate dopamine receptors.
Thiazoles are heterocyclic organic compounds containing a sulfur atom and a nitrogen atom, which are bound by two carbon atoms to form a five-membered ring, and are widely found in various natural and synthetic substances, including some pharmaceuticals and vitamins.
Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.
Cell-surface proteins that bind SEROTONIN and trigger intracellular changes which influence the behavior of cells. Several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action.
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS.
The relationship between the dose of an administered drug and the response of the organism to the drug.
One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action.
A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.
A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.
A condition characterized by inactivity, decreased responsiveness to stimuli, and a tendency to maintain an immobile posture. The limbs tend to remain in whatever position they are placed (waxy flexibility). Catalepsy may be associated with PSYCHOTIC DISORDERS (e.g., SCHIZOPHRENIA, CATATONIC), nervous system drug toxicity, and other conditions.
Study of mental processes and behavior of schizophrenics.
A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain.
Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.
The use of multiple drugs administered to the same patient, most commonly seen in elderly patients. It includes also the administration of excessive medication. Since in the United States most drugs are dispensed as single-agent formulations, polypharmacy, though using many drugs administered to the same patient, must be differentiated from DRUG COMBINATIONS, single preparations containing two or more drugs as a fixed dose, and from DRUG THERAPY, COMBINATION, two or more drugs administered separately for a combined effect. (From Segen, Dictionary of Modern Medicine, 1992)
Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
A phenothiazine used in the treatment of PSYCHOSES. Its properties and uses are generally similar to those of CHLORPROMAZINE.
Compounds containing dibenzo-1,4-thiazine. Some of them are neuroactive.
A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.
A complex involuntary response to an unexpected strong stimulus usually auditory in nature.
A serotonin receptor subtype found widely distributed in peripheral tissues where it mediates the contractile responses of variety of tissues that contain SMOOTH MUSCLE. Selective 5-HT2A receptor antagonists include KETANSERIN. The 5-HT2A subtype is also located in BASAL GANGLIA and CEREBRAL CORTEX of the BRAIN where it mediates the effects of HALLUCINOGENS such as LSD.
A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.
The practice of prescribing or using a drug outside the scope of the drug's official approved label as designated by a regulatory agency concerning the treatment of a particular disease or condition.
A condition associated with the use of certain medications and characterized by an internal sense of motor restlessness often described as an inability to resist the urge to move.
A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)
A feeling of restlessness associated with increased motor activity. This may occur as a manifestation of nervous system drug toxicity or other conditions.
Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness.
A subclass of G-protein coupled SEROTONIN receptors that couple preferentially to the GQ-G11 G-PROTEINS resulting in increased intracellular levels of INOSITOL PHOSPHATES and free CALCIUM.
A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)
A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents).
A biologically active tridecapeptide isolated from the hypothalamus. It has been shown to induce hypotension in the rat, to stimulate contraction of guinea pig ileum and rat uterus, and to cause relaxation of rat duodenum. There is also evidence that it acts as both a peripheral and a central nervous system neurotransmitter.

The social and economic effects of manic depressive illness and of its treatment in lithium clinics. (1/3659)

Advising about the employment of those who have had manic depressive episodes requires Occupational Health Physicians to obtain, with consent, an objective account of previous episodes and to appreciate the enormous range of manic and depressive manifestations. Familiarity is needed with the likely effects of treatment of episodes and the benefits and problems of prophylaxis--not just in general but in individual cases, for example, where driving is required. This article summarizes research into the effects of lithium preparations on the course of the illness, thyroid and renal function and the risk of suicide. The author found that changing from treatment of episodes to continuous prophylaxis benefited employment and personal relationships without causing body weight problems. Many patients do well in life if supported by an experienced professional team, with 61% requiring no further admissions once on lithium, and with an 86% reduction in admissions achieved in our local clinic.  (+info)

S-16924 [(R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]- pyrrolidin-3yl]-1-(4-fluorophenyl)-ethanone], a novel, potential antipsychotic with marked serotonin1A agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol. (2/3659)

S-16924 is a potential antipsychotic that displays agonist and antagonist properties at serotonin (5-HT)1A and 5-HT2A/2C receptors, respectively. In a pigeon conflict procedure, the benzodiazepine clorazepate (CLZ) increased punished responses, an action mimicked by S-16924, whereas the atypical antipsychotic clozapine and the neuroleptic haloperidol were inactive. Similarly, in a Vogel conflict paradigm in rats, CLZ increased punished responses, an action shared by S-16924 but not by clozapine or haloperidol. This action of S-16924 was abolished by the 5-HT1A antagonist WAY-100,635. Ultrasonic vocalizations in rats were inhibited by CLZ, S-16924, clozapine, and haloperidol. However, although WAY-100,635 abolished the action of S-16924, it did not affect clozapine and haloperidol. In a rat elevated plus-maze, CLZ, but not S-16924, clozapine, and haloperidol, increased open-arm entries. Like CLZ, S-16924 increased social interaction in rats, whereas clozapine and haloperidol were inactive. WAY-100,635 abolished this action of S-16924. CLZ, S-16924, clozapine, and haloperidol decreased aggressive interactions in isolated mice, but this effect of S-16924 was not blocked by WAY-100, 635. All drugs inhibited motor behavior, but the separation to anxiolytic doses was more pronounced for S-16924 than for CLZ. Finally, in freely moving rats, CLZ and S-16924, but not clozapine and haloperidol, decreased dialysis levels of 5-HT in the nucleus accumbens: this action of S-16924 was blocked by WAY-100,165. In conclusion, in contrast to haloperidol and clozapine, S-16924 possessed a broad-based profile of anxiolytic activity at doses lower than those provoking motor disruption. Its principal mechanism of action was activation of 5-HT1A (auto)receptors.  (+info)

Ergoline derivative LEK-8829-induced turning behavior in rats with unilateral striatal ibotenic acid lesions: interaction with bromocriptine. (3/3659)

LEK-8829 [9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8- aminomethylergoline bimaleinate] is an antagonist of dopamine D2 receptors and serotonin (5-HT)2 and 5-HT1A receptors in intact animals and a D1 receptor agonist in dopamine-depleted animals. In the present study, we used rats with unilateral striatal lesions with ibotenic acid (IA) to investigate the dopamine receptor activities of LEK-8829 in a model with innervated dopamine receptors. The IA-lesioned rats circled ipsilaterally when challenged with apomorphine, the mixed agonist on D1/D2 receptors. LEK-8829 induced a dose-dependent contralateral turning that was blocked by D1 receptor antagonist SCH-23390. The treatment with D1 receptor agonist SKF-82958 induced ipsilateral turning, whereas the treatment with D2 receptor antagonist haloperidol induced contralateral posture. The combined treatment with SKF-82958 and haloperidol resulted in a weak contralateral turning, indicating the possible receptor mechanism of contralateral turning induced by LEK-8829. Bromocriptine induced a weak ipsilateral turning that was blocked by haloperidol. The ipsilateral turning induced by bromocriptine was significantly potentiated by the coadministration of a low dose but not by a high dose of LEK-8829. The potentiation of turning was blocked either by SCH-23390 or by haloperidol. The potentiation of ipsilateral turning suggests the costimulation of D2 and D1 receptors by bromocriptine and LEK-8829, respectively, whereas the lack of potentiation by the highest dose of LEK-8829 may be explained by the opposing activity of LEK-8829 and bromocriptine at D2 receptors. We propose that the D2 and 5HT2 receptor-blocking and D1 receptor-stimulating profile of LEK-8829 is promising for the treatment of negative symptoms of schizophrenia.  (+info)

Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells. (4/3659)

We recently reported that clozapine behaves as a partial agonist at the cloned human m4 muscarinic receptor subtype. In the present study, we investigated whether the drug could elicit similar effects at the cloned human m1, m2, and m3 muscarinic receptor subtypes expressed in the Chinese hamster ovary (CHO) cells. Clozapine elicited a concentration-dependent stimulation of [3H]inositol phosphates accumulation in CHO cells expressing either the m1 or the m3 receptor subtype. Moreover, clozapine inhibited forskolin-stimulated cyclic AMP accumulation and enhanced [35S] GTP gamma S binding to membrane G proteins in CHO cells expressing the m2 receptor. These agonist effects of clozapine were antagonized by atropine. The intrinsic activity of clozapine was lower than that of the full cholinergic agonist carbachol, and, when the compounds were combined, clozapine potently reduced the receptor responses to carbachol. These data indicate that clozapine behaves as a partial agonist at different muscarinic receptor subtypes and may provide new hints for understanding the receptor mechanisms underlying the antipsychotic efficacy of the drug.  (+info)

Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. (5/3659)

BACKGROUND: Drug-induced psychosis is a difficult problem to manage in patients with Parkinson's disease. Multiple open-label studies have reported that treatment with clozapine at low doses ameliorates psychosis without worsening parkinsonism. METHODS: We conducted a randomized, double-blind, placebo-controlled trial of low doses of clozapine (6.25 to 50 mg per day) in 60 patients at six sites over a period of 14 months. The patients (mean age, 72 years) had idiopathic Parkinson's disease and drug-induced psychosis of at least four weeks' duration. All the patients continued to receive fixed doses of antiparkinsonian drugs during the four weeks of the trial. Blood counts were monitored weekly in all the patients. RESULTS: The mean dose of clozapine was 24.7 mg per day. The patients in the clozapine group had significantly more improvement than those in the placebo group in all three of the measures used to determine the severity of psychosis. The mean (+/-SE) scores on the Clinical Global Impression Scale improved by 1.6+/-0.3 points for the patients receiving clozapine, as compared with 0.5+/-0.2 point for those receiving placebo (P<0.001). The score on the Brief Psychiatric Rating Scale improved by 9.3+/-1.5 points for the patients receiving clozapine, as compared with 2.6+/-1.3 points for those receiving placebo (P=0.002). The score on the Scale for the Assessment of Positive Symptoms improved by 11.8+/-2.0 points for the patients receiving clozapine, as compared with 3.8+/-1.9 points for those receiving placebo (P=0.01). Seven patients treated with clozapine had an improvement of at least three on the seven-point Clinical Global Impression Scale, as compared with only one patient given placebo. Clozapine treatment improved tremor and had no deleterious effect on the severity of parkinsonism. In one patient, clozapine was discontinued because of leukopenia. CONCLUSIONS: Clozapine, at daily doses of 50 mg or less, is safe and significantly improves drug-induced psychosis without worsening parkinsonism.  (+info)

Antagonistic effects of trifluoperazine, imipramine, and chlorpromazine against acetylcholine-induced contractions in isolated rat uterus. (6/3659)

AIM: To examine the effects and affinity of some phenothizines (trifluoperazine, Tri and chlorpromazine, Chl) and antidepressant (imipramine, Imi) drugs on acetylcholine (ACh)-induced uterine contraction. METHODS: Isotonic contractions of rat uterine strips were recorded. ACh was administrated to induce maximal contraction before exchange of nutrient solution. ACh was added 5 min after the testing drugs. The nutrient solution was exchanged 4 times after each agonist (ACh or other agents) to produce maximal contraction. RESULTS: Atropine (Atr, 0.029-2.9 mumol.L-1), 4-DAMP (3.6-360 nmol.L-1), pirenzepine (Pir, 0.23-23.5 mumol.L-1), and AF-DX 116 (0.7-35.6 mumol.L-1) competitively antagonized the muscular uterine concentration induced by ACh (0.068-36068 mumol.L-1). The Schild plot was linear (r = 1.00). The pKB and slopes values (95% confidence limits) were 9.28 +/- 0.12 and 1.00 +/- 0.10 to Atr, 9.06 +/- 0.10 and 1.10 +/- 0.08 to 4-DAMP, 7.03 +/- 0.15 and 0.99 +/- 0.12 to Pir, and 5.60 +/- 0.08 and 1.00 +/- 0.19 to AF-DX 116. Tri 0.01-2 mumol.L-1 (pKB = 8.39 +/- 0.04) and Imi 94-940 nmol.L-1 (pKB = 7.21 +/- 0.10) produced also a competitive antagonism of the muscular uterine contraction induced by ACh (r = 1.00), but the slope was only 0.60 +/- 0.03 to Tri or 0.83 +/- 0.16 to Imi. Chl 2.8-5.6 mumol.L-1 produced a weak antagonism on amplitude of muscular contraction induced by the cholinomimetic. CONCLUSION: The muscarinic receptors on uterus behaved as M3 subtype. Tri and Imi, but not Chl, were competitive antagonist of muscarinic receptors of uterus. Imi behaved a simple competitive antagonist at a single site on myometrium, but Tri was not a simple competitive agent at a single site.  (+info)

The use of atypical antipsychotics in the management of schizophrenia. (7/3659)

Long-term drug treatment of schizophrenia with conventional antipsychotics has limitations: an estimated quarter to one third of patients are treatment-resistant; conventional antipsychotics have only a modest impact upon negative symptoms (poverty of thought, social withdrawal and loss of affect); and adverse effects, particularly extrapyramidal symptoms (EPS). Newer, so-called atypical, antipsychotics such as olanzapine, risperidone, sertindole and clozapine (an old drug which was re-introduced in 1990) are claimed to address these limitations. Atypical agents are, at a minimum, at least as effective as conventional drugs such as haloperidol. They also cause substantially fewer extrapyramidal symptoms. However, some other adverse effects are more common than with conventional drugs. For example, clozapine carries a significant risk of serious blood disorders, for which special monitoring is mandatory; it also causes troublesome drowsiness and increased salivation more often than conventional agents. Some atypical agents cause more weight gain or QT prolongation than older agents. The choice of therapy is, therefore, not straightforward. At present, atypical agents represent an advance for patients with severe or intolerable EPS. Most published evidence exists to support the use of clozapine, which has also been shown to be effective in schizophrenia refractory to conventional agents. However, the need for compliance with blood count monitoring and its sedative properties make careful patient selection important. The extent of any additional direct benefit offered by atypical agents on negative symptoms is not yet clear. The lack of a depot formulation for atypical drugs may pose a significant practical problem. To date, only two double-blind studies in which atypical agents were compared directly have been published. Neither provides compelling evidence for the choice of one agent over another. Atypical agents are many times more expensive than conventional drugs. Although drug treatment constitutes only a small proportion of the costs of managing schizophrenia, the additional annual cost of the use of atypical agents in, say, a quarter of the likely U.K. schizophrenic population would be about 56 M pound sterling. There is only limited evidence of cost-effectiveness. Atypical antipsychotics are not currently licensed for other conditions where conventional antipsychotics are commonly used, such as behaviour disturbance or dementia in the elderly. Their dose, and place in treatment in such cases have yet to be determined.  (+info)

Synergistic interactions between ampakines and antipsychotic drugs. (8/3659)

Tests were made for interactions between antipsychotic drugs and compounds that enhance synaptic currents mediated by alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid-type glutamate receptors ("ampakines"). Typical and atypical antipsychotic drugs decreased methamphetamine-induced hyperactivity in rats; the effects of near or even subthreshold doses of the antipsychotics were greatly enhanced by the ampakines. Interactions between the ampakine CX516 and low doses of different antipsychotics were generally additive and often synergistic. The ampakine did not exacerbate neuroleptic-induced catalepsy, indicating that the interaction between the different pharmacological classes was selective. These results suggest that positive modulators of cortical glutamatergic systems may be useful adjuncts in treating schizophrenia.  (+info)

Antipsychotic agents are a class of medications used to manage and treat psychosis, which includes symptoms such as delusions, hallucinations, paranoia, disordered thought processes, and agitated behavior. These drugs work by blocking the action of dopamine, a neurotransmitter in the brain that is believed to play a role in the development of psychotic symptoms. Antipsychotics can be broadly divided into two categories: first-generation antipsychotics (also known as typical antipsychotics) and second-generation antipsychotics (also known as atypical antipsychotics).

First-generation antipsychotics, such as chlorpromazine, haloperidol, and fluphenazine, were developed in the 1950s and have been widely used for several decades. They are generally effective in reducing positive symptoms of psychosis (such as hallucinations and delusions) but can cause significant side effects, including extrapyramidal symptoms (EPS), such as rigidity, tremors, and involuntary movements, as well as weight gain, sedation, and orthostatic hypotension.

Second-generation antipsychotics, such as clozapine, risperidone, olanzapine, quetiapine, and aripiprazole, were developed more recently and are considered to have a more favorable side effect profile than first-generation antipsychotics. They are generally effective in reducing both positive and negative symptoms of psychosis (such as apathy, anhedonia, and social withdrawal) and cause fewer EPS. However, they can still cause significant weight gain, metabolic disturbances, and sedation.

Antipsychotic agents are used to treat various psychiatric disorders, including schizophrenia, bipolar disorder, major depressive disorder with psychotic features, delusional disorder, and other conditions that involve psychosis or agitation. They can be administered orally, intramuscularly, or via long-acting injectable formulations. The choice of antipsychotic agent depends on the individual patient's needs, preferences, and response to treatment, as well as the potential for side effects. Regular monitoring of patients taking antipsychotics is essential to ensure their safety and effectiveness.

Clozapine is an atypical antipsychotic medication that is primarily used to treat schizophrenia in patients who have not responded to other antipsychotic treatments. It is also used off-label for the treatment of severe aggression, suicidal ideation, and self-injurious behavior in individuals with developmental disorders.

Clozapine works by blocking dopamine receptors in the brain, particularly the D4 receptor, which is thought to be involved in the development of schizophrenia. It also has a strong affinity for serotonin receptors, which contributes to its unique therapeutic profile.

Clozapine is considered a medication of last resort due to its potential side effects, which can include agranulocytosis (a severe decrease in white blood cell count), myocarditis (inflammation of the heart muscle), seizures, orthostatic hypotension (low blood pressure upon standing), and weight gain. Because of these risks, patients taking clozapine must undergo regular monitoring of their blood counts and other vital signs.

Despite its potential side effects, clozapine is often effective in treating treatment-resistant schizophrenia and has been shown to reduce the risk of suicide in some patients. It is available in tablet and orally disintegrating tablet formulations.

Dibenzothiazepines are a class of heterocyclic chemical compounds that contain a dibenzothiazepine ring structure. This structure is composed of a benzene ring fused to a thiazepine ring, which is itself formed by the fusion of a benzene ring and a diazepine ring (a seven-membered ring containing two nitrogen atoms).

In the medical field, dibenzothiazepines are known for their pharmacological properties and have been used in the development of various drugs. Some dibenzothiazepine derivatives exhibit antipsychotic, anxiolytic, and anticonvulsant activities. However, due to their potential for adverse effects and the availability of safer alternatives, they are not widely used in clinical practice today.

It is important to note that specific dibenzothiazepine compounds may have unique properties and uses beyond their general classification as a chemical class. Always consult medical literature or healthcare professionals for accurate information on specific drugs or compounds.

Risperidone is an atypical antipsychotic medication that is primarily used to treat certain mental/mood disorders (such as schizophrenia, bipolar disorder, and irritability associated with autistic disorder). It works by helping to restore the balance of certain natural substances in the brain. Risperidone belongs to a class of drugs called benzisoxazole derivatives.

This medication can decrease aggression and schizophrenic symptoms such as hallucinations, delusional thinking, and hostility. It may also help to improve your mood, thoughts, and behavior. Some forms of risperidone are also used for the treatment of irritability in children and adolescents with autistic disorder (a developmental disorder that affects communication and behavior).

It's important to note that this is a general medical definition, and the use of risperidone should always be under the supervision of a healthcare professional, as it can have potential side effects and risks.

Haloperidol is an antipsychotic medication, which is primarily used to treat schizophrenia and symptoms of psychosis, such as delusions, hallucinations, paranoia, or disordered thought. It may also be used to manage Tourette's disorder, tics, agitation, aggression, and hyperactivity in children with developmental disorders.

Haloperidol works by blocking the action of dopamine, a neurotransmitter in the brain, which helps to regulate mood and behavior. It is available in various forms, including tablets, liquid, and injectable solutions. The medication can cause side effects such as drowsiness, restlessness, muscle stiffness, and uncontrolled movements. In rare cases, it may also lead to more serious neurological side effects.

As with any medication, haloperidol should be taken under the supervision of a healthcare provider, who will consider the individual's medical history, current medications, and other factors before prescribing it.

Benzodiazepines are a class of psychoactive drugs that have been widely used for their sedative, hypnotic, anxiolytic, anticonvulsant, and muscle relaxant properties. They act by enhancing the inhibitory effects of gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system.

Benzodiazepines are commonly prescribed for the treatment of anxiety disorders, insomnia, seizures, and muscle spasms. They can also be used as premedication before medical procedures to produce sedation, amnesia, and anxiolysis. Some examples of benzodiazepines include diazepam (Valium), alprazolam (Xanax), clonazepam (Klonopin), lorazepam (Ativan), and temazepam (Restoril).

While benzodiazepines are effective in treating various medical conditions, they can also cause physical dependence and withdrawal symptoms. Long-term use of benzodiazepines can lead to tolerance, meaning that higher doses are needed to achieve the same effect. Abrupt discontinuation of benzodiazepines can result in severe withdrawal symptoms, including seizures, hallucinations, and anxiety. Therefore, it is important to taper off benzodiazepines gradually under medical supervision.

Benzodiazepines are classified as Schedule IV controlled substances in the United States due to their potential for abuse and dependence. It is essential to use them only as directed by a healthcare provider and to be aware of their potential risks and benefits.

Schizophrenia is a severe mental disorder characterized by disturbances in thought, perception, emotion, and behavior. It often includes hallucinations (usually hearing voices), delusions, paranoia, and disorganized speech and behavior. The onset of symptoms typically occurs in late adolescence or early adulthood. Schizophrenia is a complex, chronic condition that requires ongoing treatment and management. It significantly impairs social and occupational functioning, and it's often associated with reduced life expectancy due to comorbid medical conditions. The exact causes of schizophrenia are not fully understood, but research suggests that genetic, environmental, and neurodevelopmental factors play a role in its development.

Butyrophenones are a group of synthetic antipsychotic drugs that are primarily used to treat symptoms of schizophrenia and other psychotic disorders. They act as dopamine receptor antagonists, which means they block the action of dopamine, a neurotransmitter in the brain associated with mood, motivation, and pleasure.

Some examples of butyrophenones include haloperidol, droperidol, and benperidol. These drugs are known for their potent antipsychotic effects and can also be used to manage agitation, aggression, and other behavioral disturbances in patients with various psychiatric and neurological disorders.

In addition to their antipsychotic properties, butyrophenones have been used off-label for their sedative and analgesic effects. However, they are associated with a range of side effects, including extrapyramidal symptoms (EPS), such as involuntary muscle spasms and tremors, as well as other neurological and cardiovascular adverse reactions. Therefore, their use is typically reserved for cases where other treatments have been ineffective or contraindicated.

Isoindoles are not typically considered in the context of medical definitions, as they are organic compounds that do not have direct relevance to medical terminology or human disease. However, isoindole is a heterocyclic compound that contains two nitrogen atoms in its structure and can be found in some naturally occurring substances and synthetic drugs.

Isoindoles are aromatic compounds, which means they have a stable ring structure with delocalized electrons. They can form the core structure of various bioactive molecules, including alkaloids, which are nitrogen-containing compounds that occur naturally in plants and animals and can have various pharmacological activities.

Some isoindole derivatives have been synthesized and studied for their potential medicinal properties, such as anti-inflammatory, antiviral, and anticancer activities. However, these compounds are still in the early stages of research and development and have not yet been approved for medical use.

Therefore, while isoindoles themselves do not have a specific medical definition, they can be relevant to the study of medicinal chemistry and drug discovery.

Dopamine D2 receptor is a type of metabotropic G protein-coupled receptor that binds to the neurotransmitter dopamine. It is one of five subtypes of dopamine receptors (D1-D5) and is encoded by the gene DRD2. The activation of D2 receptors leads to a decrease in the activity of adenylyl cyclase, which results in reduced levels of cAMP and modulation of ion channels.

D2 receptors are widely distributed throughout the central nervous system (CNS) and play important roles in various physiological functions, including motor control, reward processing, emotion regulation, and cognition. They are also involved in several neurological and psychiatric disorders, such as Parkinson's disease, schizophrenia, drug addiction, and Tourette syndrome.

D2 receptors have two main subtypes: D2 short (D2S) and D2 long (D2L). The D2S subtype is primarily located in the presynaptic terminals and functions as an autoreceptor that regulates dopamine release, while the D2L subtype is mainly found in the postsynaptic neurons and modulates intracellular signaling pathways.

Antipsychotic drugs, which are used to treat schizophrenia and other psychiatric disorders, work by blocking D2 receptors. However, excessive blockade of these receptors can lead to side effects such as extrapyramidal symptoms (EPS), tardive dyskinesia, and hyperprolactinemia. Therefore, the development of drugs that selectively target specific subtypes of dopamine receptors is an active area of research in the field of neuropsychopharmacology.

Dopamine antagonists are a class of drugs that block the action of dopamine, a neurotransmitter in the brain associated with various functions including movement, motivation, and emotion. These drugs work by binding to dopamine receptors and preventing dopamine from attaching to them, which can help to reduce the symptoms of certain medical conditions such as schizophrenia, bipolar disorder, and gastroesophageal reflux disease (GERD).

There are several types of dopamine antagonists, including:

1. Typical antipsychotics: These drugs are primarily used to treat psychosis, including schizophrenia and delusional disorders. Examples include haloperidol, chlorpromazine, and fluphenazine.
2. Atypical antipsychotics: These drugs are also used to treat psychosis but have fewer side effects than typical antipsychotics. They may also be used to treat bipolar disorder and depression. Examples include risperidone, olanzapine, and quetiapine.
3. Antiemetics: These drugs are used to treat nausea and vomiting. Examples include metoclopramide and prochlorperazine.
4. Dopamine agonists: While not technically dopamine antagonists, these drugs work by stimulating dopamine receptors and can be used to treat conditions such as Parkinson's disease. However, they can also have the opposite effect and block dopamine receptors in high doses, making them functionally similar to dopamine antagonists.

Common side effects of dopamine antagonists include sedation, weight gain, and movement disorders such as tardive dyskinesia. It's important to use these drugs under the close supervision of a healthcare provider to monitor for side effects and adjust the dosage as needed.

Pirenzepine is a medication that belongs to a class of drugs called anticholinergics or parasympatholytics. It works by blocking the action of acetylcholine, a neurotransmitter in the body, on certain types of muscarinic receptors.

Pirenzepine is primarily used to treat peptic ulcers and gastroesophageal reflux disease (GERD) by reducing the production of stomach acid. It may also be used to manage symptoms of irritable bowel syndrome, such as abdominal pain and diarrhea.

The medication is available in the form of tablets or gel for topical application. Side effects of pirenzepine may include dry mouth, blurred vision, constipation, dizziness, and difficulty urinating. It should be used with caution in people with glaucoma, benign prostatic hyperplasia, or other conditions that may be exacerbated by anticholinergic drugs.

It is important to note that this definition is for informational purposes only and should not be taken as medical advice. Always consult with a healthcare professional before starting any new medication.

Raclopride is not a medical condition but a drug that belongs to the class of dopamine receptor antagonists. It's primarily used in research and diagnostic settings as a radioligand in positron emission tomography (PET) scans to visualize and measure the distribution and availability of dopamine D2 and D3 receptors in the brain.

In simpler terms, Raclopride is a compound that can be labeled with a radioactive isotope and then introduced into the body to track the interaction between the radioligand and specific receptors (in this case, dopamine D2 and D3 receptors) in the brain. This information can help researchers and clinicians better understand neurochemical processes and disorders related to dopamine dysfunction, such as Parkinson's disease, schizophrenia, and drug addiction.

It is important to note that Raclopride is not used as a therapeutic agent in clinical practice due to its short half-life and the potential for side effects associated with dopamine receptor blockade.

Psychotic disorders are a group of severe mental health conditions characterized by distorted perceptions, thoughts, and emotions that lead to an inability to recognize reality. The two most common symptoms of psychotic disorders are hallucinations and delusions. Hallucinations are when a person sees, hears, or feels things that aren't there, while delusions are fixed, false beliefs that are not based on reality.

Other symptoms may include disorganized speech, disorganized behavior, catatonic behavior, and negative symptoms such as apathy and lack of emotional expression. Schizophrenia is the most well-known psychotic disorder, but other types include schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, and substance-induced psychotic disorder.

Psychotic disorders can be caused by a variety of factors, including genetics, brain chemistry imbalances, trauma, and substance abuse. Treatment typically involves a combination of medication, therapy, and support services to help manage symptoms and improve quality of life.

Apomorphine is a non-selective dopamine receptor agonist, which means that it activates dopamine receptors in the brain. It has a high affinity for D1 and D2 dopamine receptors and is used medically to treat Parkinson's disease, particularly in cases of severe or intractable motor fluctuations.

Apomorphine can be administered subcutaneously (under the skin) as a solution or as a sublingual (under the tongue) film. It works by stimulating dopamine receptors in the brain, which helps to reduce the symptoms of Parkinson's disease such as stiffness, tremors, and difficulty with movement.

In addition to its use in Parkinson's disease, apomorphine has also been investigated for its potential therapeutic benefits in other neurological disorders, including alcohol use disorder and drug addiction. However, more research is needed to establish its safety and efficacy in these conditions.

Piperazines are a class of heterocyclic organic compounds that contain a seven-membered ring with two nitrogen atoms at positions 1 and 4. They have the molecular formula N-NRR' where R and R' can be alkyl or aryl groups. Piperazines have a wide range of uses in pharmaceuticals, agrochemicals, and as building blocks in organic synthesis.

In a medical context, piperazines are used in the manufacture of various drugs, including some antipsychotics, antidepressants, antihistamines, and anti-worm medications. For example, the antipsychotic drug trifluoperazine and the antidepressant drug nefazodone both contain a piperazine ring in their chemical structure.

However, it's important to note that some piperazines are also used as recreational drugs due to their stimulant and euphoric effects. These include compounds such as BZP (benzylpiperazine) and TFMPP (trifluoromethylphenylpiperazine), which have been linked to serious health risks, including addiction, seizures, and death. Therefore, the use of these substances should be avoided.

Dopamine D3 receptors are a type of G protein-coupled receptor that bind to the neurotransmitter dopamine. They are classified as part of the D2-like family of dopamine receptors, which also includes the D2 and D4 receptors. The D3 receptor is primarily expressed in the limbic areas of the brain, including the hippocampus and the nucleus accumbens, where it plays a role in regulating motivation, reward, and cognition.

D3 receptors have been found to be involved in several neurological and psychiatric disorders, such as Parkinson's disease, schizophrenia, and drug addiction. In Parkinson's disease, the loss of dopamine-producing neurons in the substantia nigra results in a decrease in dopamine levels and an increase in D3 receptor expression. This increase in D3 receptor expression has been linked to the development of motor symptoms such as bradykinesia and rigidity.

In schizophrenia, antipsychotic medications that block D2-like receptors, including D3 receptors, are used to treat positive symptoms such as hallucinations and delusions. However, selective D3 receptor antagonists have also been shown to have potential therapeutic effects in treating negative symptoms of schizophrenia, such as apathy and anhedonia.

In drug addiction, D3 receptors have been found to play a role in the rewarding effects of drugs of abuse, such as cocaine and amphetamines. Selective D3 receptor antagonists have shown promise in reducing drug-seeking behavior and preventing relapse in animal models of addiction.

Overall, dopamine D3 receptors play an important role in several neurological and psychiatric disorders, and further research is needed to fully understand their functions and potential therapeutic uses.

Dopamine receptors are a type of G protein-coupled receptor that bind to and respond to the neurotransmitter dopamine. There are five subtypes of dopamine receptors (D1-D5), which are classified into two families based on their structure and function: D1-like (D1 and D5) and D2-like (D2, D3, and D4).

Dopamine receptors play a crucial role in various physiological processes, including movement, motivation, reward, cognition, emotion, and neuroendocrine regulation. They are widely distributed throughout the central nervous system, with high concentrations found in the basal ganglia, limbic system, and cortex.

Dysfunction of dopamine receptors has been implicated in several neurological and psychiatric disorders, such as Parkinson's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD), drug addiction, and depression. Therefore, drugs targeting dopamine receptors have been developed for the treatment of these conditions.

Dopamine agonists are a class of medications that mimic the action of dopamine, a neurotransmitter in the brain that regulates movement, emotion, motivation, and reinforcement of rewarding behaviors. These medications bind to dopamine receptors in the brain and activate them, leading to an increase in dopaminergic activity.

Dopamine agonists are used primarily to treat Parkinson's disease, a neurological disorder characterized by motor symptoms such as tremors, rigidity, bradykinesia (slowness of movement), and postural instability. By increasing dopaminergic activity in the brain, dopamine agonists can help alleviate some of these symptoms.

Examples of dopamine agonists include:

1. Pramipexole (Mirapex)
2. Ropinirole (Requip)
3. Rotigotine (Neupro)
4. Apomorphine (Apokyn)

Dopamine agonists may also be used off-label to treat other conditions, such as restless legs syndrome or certain types of dopamine-responsive dystonia. However, these medications can have significant side effects, including nausea, dizziness, orthostatic hypotension, compulsive behaviors (such as gambling, shopping, or sexual addiction), and hallucinations. Therefore, they should be used with caution and under the close supervision of a healthcare provider.

Thiazoles are organic compounds that contain a heterocyclic ring consisting of a nitrogen atom and a sulfur atom, along with two carbon atoms and two hydrogen atoms. They have the chemical formula C3H4NS. Thiazoles are present in various natural and synthetic substances, including some vitamins, drugs, and dyes. In the context of medicine, thiazole derivatives have been developed as pharmaceuticals for their diverse biological activities, such as anti-inflammatory, antifungal, antibacterial, and antihypertensive properties. Some well-known examples include thiazide diuretics (e.g., hydrochlorothiazide) used to treat high blood pressure and edema, and the antidiabetic drug pioglitazone.

Isoxazoles are not a medical term, but a chemical compound. They are organic compounds containing a five-membered ring consisting of one nitrogen atom, one oxygen atom, and three carbon atoms. Isoxazoles have various applications in the pharmaceutical industry as they can be used to synthesize different drugs. Some isoxazole derivatives have been studied for their potential medicinal properties, such as anti-inflammatory, analgesic, and antipyretic effects. However, isoxazoles themselves are not a medical diagnosis or treatment.

Serotonin receptors are a type of cell surface receptor that bind to the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT). They are widely distributed throughout the body, including the central and peripheral nervous systems, where they play important roles in regulating various physiological processes such as mood, appetite, sleep, memory, learning, and cognition.

There are seven different classes of serotonin receptors (5-HT1 to 5-HT7), each with multiple subtypes, that exhibit distinct pharmacological properties and signaling mechanisms. These receptors are G protein-coupled receptors (GPCRs) or ligand-gated ion channels, which activate intracellular signaling pathways upon serotonin binding.

Serotonin receptors have been implicated in various neurological and psychiatric disorders, including depression, anxiety, schizophrenia, and migraine. Therefore, selective serotonin receptor agonists or antagonists are used as therapeutic agents for the treatment of these conditions.

Serotonin antagonists are a class of drugs that block the action of serotonin, a neurotransmitter, at specific receptor sites in the brain and elsewhere in the body. They work by binding to the serotonin receptors without activating them, thereby preventing the natural serotonin from binding and transmitting signals.

Serotonin antagonists are used in the treatment of various conditions such as psychiatric disorders, migraines, and nausea and vomiting associated with cancer chemotherapy. They can have varying degrees of affinity for different types of serotonin receptors (e.g., 5-HT2A, 5-HT3, etc.), which contributes to their specific therapeutic effects and side effect profiles.

Examples of serotonin antagonists include ondansetron (used to treat nausea and vomiting), risperidone and olanzapine (used to treat psychiatric disorders), and methysergide (used to prevent migraines). It's important to note that these medications should be used under the supervision of a healthcare provider, as they can have potential risks and interactions with other drugs.

A dose-response relationship in the context of drugs refers to the changes in the effects or symptoms that occur as the dose of a drug is increased or decreased. Generally, as the dose of a drug is increased, the severity or intensity of its effects also increases. Conversely, as the dose is decreased, the effects of the drug become less severe or may disappear altogether.

The dose-response relationship is an important concept in pharmacology and toxicology because it helps to establish the safe and effective dosage range for a drug. By understanding how changes in the dose of a drug affect its therapeutic and adverse effects, healthcare providers can optimize treatment plans for their patients while minimizing the risk of harm.

The dose-response relationship is typically depicted as a curve that shows the relationship between the dose of a drug and its effect. The shape of the curve may vary depending on the drug and the specific effect being measured. Some drugs may have a steep dose-response curve, meaning that small changes in the dose can result in large differences in the effect. Other drugs may have a more gradual dose-response curve, where larger changes in the dose are needed to produce significant effects.

In addition to helping establish safe and effective dosages, the dose-response relationship is also used to evaluate the potential therapeutic benefits and risks of new drugs during clinical trials. By systematically testing different doses of a drug in controlled studies, researchers can identify the optimal dosage range for the drug and assess its safety and efficacy.

Dopamine is a type of neurotransmitter, which is a chemical messenger that transmits signals in the brain and nervous system. It plays several important roles in the body, including:

* Regulation of movement and coordination
* Modulation of mood and motivation
* Control of the reward and pleasure centers of the brain
* Regulation of muscle tone
* Involvement in memory and attention

Dopamine is produced in several areas of the brain, including the substantia nigra and the ventral tegmental area. It is released by neurons (nerve cells) and binds to specific receptors on other neurons, where it can either excite or inhibit their activity.

Abnormalities in dopamine signaling have been implicated in several neurological and psychiatric conditions, including Parkinson's disease, schizophrenia, and addiction.

Thioridazine is an antipsychotic medication that belongs to the class of phenothiazines. It works by blocking dopamine receptors in the brain, which helps to reduce psychotic symptoms such as delusions, hallucinations, and disordered thought processes. Thioridazine is used to treat schizophrenia and other mental disorders associated with anxiety, agitation, or hostility.

It's important to note that thioridazine has been associated with serious side effects, including prolongation of the QT interval on the electrocardiogram (ECG), which can lead to potentially fatal arrhythmias. Therefore, its use is generally reserved for patients who have not responded to other antipsychotic medications or who cannot tolerate them. Thioridazine has been withdrawn from the market in many countries due to these safety concerns.

Sprague-Dawley rats are a strain of albino laboratory rats that are widely used in scientific research. They were first developed by researchers H.H. Sprague and R.C. Dawley in the early 20th century, and have since become one of the most commonly used rat strains in biomedical research due to their relatively large size, ease of handling, and consistent genetic background.

Sprague-Dawley rats are outbred, which means that they are genetically diverse and do not suffer from the same limitations as inbred strains, which can have reduced fertility and increased susceptibility to certain diseases. They are also characterized by their docile nature and low levels of aggression, making them easier to handle and study than some other rat strains.

These rats are used in a wide variety of research areas, including toxicology, pharmacology, nutrition, cancer, and behavioral studies. Because they are genetically diverse, Sprague-Dawley rats can be used to model a range of human diseases and conditions, making them an important tool in the development of new drugs and therapies.

Catalepsy is a medical condition characterized by a trance-like state, with reduced sensitivity to pain and external stimuli, muscular rigidity, and fixed postures. In this state, the person's body may maintain any position in which it is placed for a long time, and there is often a decreased responsiveness to social cues or communication attempts.

Catalepsy can be a symptom of various medical conditions, including neurological disorders such as epilepsy, Parkinson's disease, or brain injuries. It can also occur in the context of mental health disorders, such as severe depression, catatonic schizophrenia, or dissociative identity disorder.

In some cases, catalepsy may be induced intentionally through hypnosis or other forms of altered consciousness practices. However, when it occurs spontaneously or as a symptom of an underlying medical condition, it can be a serious concern and requires medical evaluation and treatment.

I must clarify that there is no such thing as "Schizophrenic Psychology." The term schizophrenia is used to describe a specific and serious mental disorder that affects how a person thinks, feels, and behaves. It's important not to use the term casually or inaccurately, as it can perpetuate stigma and misunderstanding about the condition.

Schizophrenia is characterized by symptoms such as hallucinations (hearing or seeing things that aren't there), delusions (false beliefs that are not based on reality), disorganized speech, and grossly disorganized or catatonic behavior. These symptoms can impair a person's ability to function in daily life, maintain relationships, and experience emotions appropriately.

If you have any questions related to mental health conditions or psychology, I would be happy to provide accurate information and definitions.

"Wistar rats" are a strain of albino rats that are widely used in laboratory research. They were developed at the Wistar Institute in Philadelphia, USA, and were first introduced in 1906. Wistar rats are outbred, which means that they are genetically diverse and do not have a fixed set of genetic characteristics like inbred strains.

Wistar rats are commonly used as animal models in biomedical research because of their size, ease of handling, and relatively low cost. They are used in a wide range of research areas, including toxicology, pharmacology, nutrition, cancer, cardiovascular disease, and behavioral studies. Wistar rats are also used in safety testing of drugs, medical devices, and other products.

Wistar rats are typically larger than many other rat strains, with males weighing between 500-700 grams and females weighing between 250-350 grams. They have a lifespan of approximately 2-3 years. Wistar rats are also known for their docile and friendly nature, making them easy to handle and work with in the laboratory setting.

Basal ganglia diseases are a group of neurological disorders that affect the function of the basal ganglia, which are clusters of nerve cells located deep within the brain. The basal ganglia play a crucial role in controlling movement and coordination. When they are damaged or degenerate, it can result in various motor symptoms such as tremors, rigidity, bradykinesia (slowness of movement), and difficulty with balance and walking.

Some examples of basal ganglia diseases include:

1. Parkinson's disease - a progressive disorder that affects movement due to the death of dopamine-producing cells in the basal ganglia.
2. Huntington's disease - an inherited neurodegenerative disorder that causes uncontrolled movements, emotional problems, and cognitive decline.
3. Dystonia - a movement disorder characterized by sustained or intermittent muscle contractions that cause twisting and repetitive movements or abnormal postures.
4. Wilson's disease - a rare genetic disorder that causes excessive copper accumulation in the liver and brain, leading to neurological and psychiatric symptoms.
5. Progressive supranuclear palsy (PSP) - a rare brain disorder that affects movement, gait, and balance, as well as speech and swallowing.
6. Corticobasal degeneration (CBD) - a rare neurological disorder characterized by progressive loss of nerve cells in the cerebral cortex and basal ganglia, leading to stiffness, rigidity, and difficulty with movement and coordination.

Treatment for basal ganglia diseases varies depending on the specific diagnosis and symptoms but may include medication, surgery, physical therapy, or a combination of these approaches.

Chlorpromazine is a type of antipsychotic medication, also known as a phenothiazine. It works by blocking dopamine receptors in the brain, which helps to reduce the symptoms of psychosis such as hallucinations, delusions, and disordered thinking. Chlorpromazine is used to treat various mental health conditions including schizophrenia, bipolar disorder, and severe behavioral problems in children. It may also be used for the short-term management of severe anxiety or agitation, and to control nausea and vomiting.

Like all medications, chlorpromazine can have side effects, which can include drowsiness, dry mouth, blurred vision, constipation, weight gain, and sexual dysfunction. More serious side effects may include neurological symptoms such as tremors, rigidity, or abnormal movements, as well as cardiovascular problems such as low blood pressure or irregular heart rhythms. It is important for patients to be monitored closely by their healthcare provider while taking chlorpromazine, and to report any unusual symptoms or side effects promptly.

Perphenazine is an antipsychotic medication that belongs to the class of phenothiazines. It works by blocking dopamine receptors in the brain, which helps to reduce psychotic symptoms such as delusions, hallucinations, and disordered thinking. Perphenazine is used to treat various mental disorders, including schizophrenia, psychotic disorders, and severe agitation or aggression in people with developmental disabilities. It may also be used for the short-term treatment of severe anxiety or depression that does not respond to other treatments.

Perphenazine can cause side effects such as drowsiness, dizziness, restlessness, dry mouth, constipation, and weight gain. More serious side effects may include neurological symptoms such as tremors, stiffness, and uncontrolled muscle movements, which may indicate a condition called tardive dyskinesia. Perphenazine can also cause cardiovascular side effects such as low blood pressure, irregular heartbeat, and increased heart rate. It is important to monitor patients taking perphenazine for these and other potential side effects.

It's worth noting that the use of antipsychotic medications like perphenazine should be based on a thorough evaluation of the patient's symptoms, medical history, and other factors. The decision to prescribe this medication should be made carefully, taking into account its benefits and risks, as well as any alternative treatment options.

Polypharmacy is the use of multiple medications by a patient, especially when too many forms of medication are used by a patient, inappropriately or, when there is a lack of indication for some of the drugs used. It is often seen in elderly patients who may be prescribed numerous medications by different healthcare providers that can increase the risk of adverse drug reactions, interactions, and impaired cognitive function. The term does not necessarily have a negative connotation, as polypharmacy can also refer to the complex process of managing multiple chronic conditions with appropriate medication therapy. However, it is often used to describe a situation where the number of medications being taken by a patient poses a significant risk to their health.

Drug-induced dyskinesia is a movement disorder that is characterized by involuntary muscle movements or abnormal posturing of the body. It is a side effect that can occur from the long-term use or high doses of certain medications, particularly those used to treat Parkinson's disease and psychosis.

The symptoms of drug-induced dyskinesia can vary in severity and may include rapid, involuntary movements of the limbs, face, or tongue; twisting or writhing movements; and abnormal posturing of the arms, legs, or trunk. These symptoms can be distressing and negatively impact a person's quality of life.

The exact mechanism by which certain medications cause dyskinesia is not fully understood, but it is thought to involve changes in the levels of dopamine, a neurotransmitter that plays a key role in regulating movement. In some cases, adjusting the dose or switching to a different medication may help alleviate the symptoms of drug-induced dyskinesia. However, in severe cases, additional treatments such as deep brain stimulation or botulinum toxin injections may be necessary.

Fluphenazine is an antipsychotic medication that belongs to the class of phenothiazines. It works by blocking the action of dopamine, a neurotransmitter in the brain, which helps to reduce the symptoms of psychosis such as delusions, hallucinations, and disordered thought.

Fluphenazine is available in several forms, including oral tablets, orally disintegrating tablets, and injectable solutions. It may be used for the treatment of schizophrenia, psychotic disorders, and other conditions associated with elevated levels of dopamine in the brain.

Like all antipsychotic medications, fluphenazine can cause side effects, including extrapyramidal symptoms (EPS), such as stiffness, tremors, and spasms of the face and neck muscles, as well as other systemic side effects like weight gain, sedation, and orthostatic hypotension. It is essential to use fluphenazine under the close supervision of a healthcare provider who can monitor for side effects and adjust the dosage accordingly.

Phenothiazines are a class of heterocyclic organic compounds that contain a phenothiazine nucleus, which consists of a pair of benzene rings fused to a thiazine ring. They have been widely used in medicine as antipsychotic drugs for the treatment of various mental disorders such as schizophrenia and bipolar disorder.

Phenothiazines work by blocking dopamine receptors in the brain, which helps to reduce the symptoms of psychosis such as hallucinations, delusions, and disordered thinking. They also have sedative and antiemetic (anti-nausea) effects. However, they can cause a range of side effects including extrapyramidal symptoms (involuntary muscle movements), tardive dyskinesia (irreversible movement disorder), and neuroleptic malignant syndrome (a rare but potentially fatal reaction to antipsychotic drugs).

Examples of phenothiazine drugs include chlorpromazine, thioridazine, and promethazine. While they have been largely replaced by newer atypical antipsychotics, phenothiazines are still used in some cases due to their lower cost and effectiveness in treating certain symptoms.

Phencyclidine (PCP) is a dissociative drug that was originally developed as an intravenous anesthetic in the 1950s. It can lead to distortions of time, space and body image, hallucinations, and a sense of physical invulnerability.

It can also cause numbness, loss of coordination, and aggressive behavior. High doses can lead to seizures, coma, and death. Long-term use can lead to memory loss, difficulties with speech and thinking, and mental health issues such as depression and suicidal thoughts. It is classified as a Schedule II drug in the United States, indicating it has a high potential for abuse but also an accepted medical use.

A startle reaction is a natural, defensive response to an unexpected stimulus that is characterized by a sudden contraction of muscles, typically in the face, neck, and arms. It's a reflexive action that occurs involuntarily and is mediated by the brainstem. The startle reaction can be observed in many different species, including humans, and is thought to have evolved as a protective mechanism to help organisms respond quickly to potential threats. In addition to the muscle contraction, the startle response may also include other physiological changes such as an increase in heart rate and blood pressure.

A serotonin receptor, specifically the 5-HT2A subtype (5-hydroxytryptamine 2A receptor), is a type of G protein-coupled receptor found in the cell membrane. It is activated by the neurotransmitter serotonin and plays a role in regulating various physiological processes, including mood, cognition, sleep, and sensory perception.

The 5-HT2A receptor is widely distributed throughout the central nervous system and has been implicated in several neurological and psychiatric disorders, such as depression, anxiety, schizophrenia, and migraine. It is also the primary target of several psychoactive drugs, including hallucinogens like LSD and psilocybin, as well as atypical antipsychotics used to treat conditions like schizophrenia.

The 5-HT2A receptor signals through a G protein called Gq, which activates a signaling cascade that ultimately leads to the activation of phospholipase C and the production of second messengers such as inositol trisphosphate (IP3) and diacylglycerol (DAG). These second messengers then go on to modulate various cellular processes, including the release of neurotransmitters and the regulation of gene expression.

Quinolones are a class of antibacterial agents that are widely used in medicine to treat various types of infections caused by susceptible bacteria. These synthetic drugs contain a chemical structure related to quinoline and have broad-spectrum activity against both Gram-positive and Gram-negative bacteria. Quinolones work by inhibiting the bacterial DNA gyrase or topoisomerase IV enzymes, which are essential for bacterial DNA replication, transcription, and repair.

The first quinolone antibiotic was nalidixic acid, discovered in 1962. Since then, several generations of quinolones have been developed, with each generation having improved antibacterial activity and a broader spectrum of action compared to the previous one. The various generations of quinolones include:

1. First-generation quinolones (e.g., nalidixic acid): Primarily used for treating urinary tract infections caused by Gram-negative bacteria.
2. Second-generation quinolones (e.g., ciprofloxacin, ofloxacin, norfloxacin): These drugs have improved activity against both Gram-positive and Gram-negative bacteria and are used to treat a wider range of infections, including respiratory, gastrointestinal, and skin infections.
3. Third-generation quinolones (e.g., levofloxacin, sparfloxacin, grepafloxacin): These drugs have enhanced activity against Gram-positive bacteria, including some anaerobes and atypical organisms like Legionella and Mycoplasma species.
4. Fourth-generation quinolones (e.g., moxifloxacin, gatifloxacin): These drugs have the broadest spectrum of activity, including enhanced activity against Gram-positive bacteria, anaerobes, and some methicillin-resistant Staphylococcus aureus (MRSA) strains.

Quinolones are generally well-tolerated, but like all medications, they can have side effects. Common adverse reactions include gastrointestinal symptoms (nausea, vomiting, diarrhea), headache, and dizziness. Serious side effects, such as tendinitis, tendon rupture, peripheral neuropathy, and QT interval prolongation, are less common but can occur, particularly in older patients or those with underlying medical conditions. The use of quinolones should be avoided or used cautiously in these populations.

Quinolone resistance has become an increasing concern due to the widespread use of these antibiotics. Bacteria can develop resistance through various mechanisms, including chromosomal mutations and the acquisition of plasmid-mediated quinolone resistance genes. The overuse and misuse of quinolones contribute to the emergence and spread of resistant strains, which can limit treatment options for severe infections caused by these bacteria. Therefore, it is essential to use quinolones judiciously and only when clinically indicated, to help preserve their effectiveness and prevent further resistance development.

Off-label use refers to the practice of prescribing or using pharmaceutical drugs for purposes, dosages, patient populations, or routes of administration that are not included in the approved labeling of the drug by the regulatory authority, such as the U.S. Food and Drug Administration (FDA). It is not illegal or unethical for physicians to prescribe medications off-label when they judge that it is medically appropriate for their patients. However, manufacturers are prohibited from promoting their drugs for off-label uses.

Drug-induced akathisia is a type of movement disorder that is a side effect of certain medications. The term "akathisia" comes from the Greek words "a-," meaning "without," and "kathisia," meaning "sitting." It is characterized by a subjective feeling of restlessness and an uncontrollable urge to be in constant motion, accompanied by objective motor symptoms such as fidgeting, rocking, or pacing.

Drug-induced akathisia is most commonly associated with the use of antipsychotic medications, particularly those that block dopamine receptors in the brain. Other drugs that have been linked to akathisia include certain antidepressants, anti-nausea medications, and some beta blockers used to treat heart conditions.

The symptoms of drug-induced akathisia can range from mild to severe and may include:

* A subjective feeling of inner restlessness or anxiety
* An uncontrollable urge to move, such as fidgeting, rocking, or pacing
* Difficulty sitting still or lying down
* Agitation and irritability
* Sleep disturbances
* Depression or dysphoria
* Suicidal thoughts or behaviors (in severe cases)

The symptoms of drug-induced akathisia can be distressing and may contribute to noncompliance with medication treatment. In some cases, the symptoms may resolve on their own after a period of time, but in other cases, they may persist or worsen, requiring a change in medication or the addition of other medications to manage the symptoms. It is important for individuals who are taking medications that have been associated with akathisia to report any new or worsening symptoms to their healthcare provider as soon as possible.

Sulpiride is an antipsychotic drug that belongs to the chemical class of benzamides. It primarily acts as a selective dopamine D2 and D3 receptor antagonist. Sulpiride is used in the treatment of various psychiatric disorders such as schizophrenia, psychosis, anxiety, and depression. In addition, it has been found to be effective in managing gastrointestinal disorders like gastroparesis due to its prokinetic effects on the gastrointestinal tract.

The medical definition of Sulpiride is as follows:

Sulpiride (INN, BAN), also known as Sultopride (USAN) or SP, is a selective dopamine D2 and D3 receptor antagonist used in the treatment of various psychiatric disorders such as schizophrenia, psychosis, anxiety, and depression. It has been found to be effective in managing gastrointestinal disorders like gastroparesis due to its prokinetic effects on the gastrointestinal tract. Sulpiride is available under various brand names worldwide, including Dogmatil, Sulpitac, and Espirid."

Please note that this definition includes information about the drug's therapeutic uses, which are essential aspects of understanding a medication in its entirety.

Psychomotor agitation is a state of increased physical activity and purposeless or semi-purposeful voluntary movements, usually associated with restlessness, irritability, and cognitive impairment. It can be a manifestation of various medical and neurological conditions such as delirium, dementia, bipolar disorder, schizophrenia, and substance withdrawal. Psychomotor agitation may also increase the risk of aggressive behavior and physical harm to oneself or others. Appropriate evaluation and management are necessary to address the underlying cause and alleviate symptoms.

Psychiatric Status Rating Scales are standardized assessment tools used by mental health professionals to evaluate and rate the severity of a person's psychiatric symptoms and functioning. These scales provide a systematic and structured approach to measuring various aspects of an individual's mental health, such as mood, anxiety, psychosis, behavior, and cognitive abilities.

The purpose of using Psychiatric Status Rating Scales is to:

1. Assess the severity and improvement of psychiatric symptoms over time.
2. Aid in diagnostic decision-making and treatment planning.
3. Monitor treatment response and adjust interventions accordingly.
4. Facilitate communication among mental health professionals about a patient's status.
5. Provide an objective basis for research and epidemiological studies.

Examples of Psychiatric Status Rating Scales include:

1. Clinical Global Impression (CGI): A brief, subjective rating scale that measures overall illness severity, treatment response, and improvement.
2. Positive and Negative Syndrome Scale (PANSS): A comprehensive scale used to assess the symptoms of psychosis, including positive, negative, and general psychopathology domains.
3. Hamilton Rating Scale for Depression (HRSD) or Montgomery-Åsberg Depression Rating Scale (MADRS): Scales used to evaluate the severity of depressive symptoms.
4. Young Mania Rating Scale (YMRS): A scale used to assess the severity of manic or hypomanic symptoms.
5. Brief Psychiatric Rating Scale (BPRS) or Symptom Checklist-90 Revised (SCL-90-R): Scales that measure a broad range of psychiatric symptoms and psychopathology.
6. Global Assessment of Functioning (GAF): A scale used to rate an individual's overall psychological, social, and occupational functioning on a hypothetical continuum of mental health-illness.

It is important to note that Psychiatric Status Rating Scales should be administered by trained mental health professionals to ensure accurate and reliable results.

'Receptors, Serotonin, 5-HT2' refer to a specific family of serotonin receptors that are activated by the neurotransmitter serotonin (5-hydroxytryptamine or 5-HT). These receptors are G protein-coupled receptors and are further divided into several subtypes, including 5-HT2A, 5-HT2B, and 5-HT2C. They are widely distributed throughout the body, including the central nervous system, cardiovascular system, gastrointestinal tract, and respiratory system.

The 5-HT2 receptors play a role in various physiological processes, such as neurotransmission, vasoconstriction, smooth muscle contraction, and cell growth regulation. They are also involved in several pathophysiological conditions, including psychiatric disorders (e.g., depression, anxiety, schizophrenia), migraine, cardiovascular diseases, and pulmonary hypertension.

The 5-HT2 receptors have been a focus of drug development for various therapeutic areas. For example, atypical antipsychotics used to treat schizophrenia work by blocking the 5-HT2A receptor, while certain migraine medications act as agonists at the 5-HT1B/1D and 5-HT2C receptors. However, drugs targeting these receptors must be carefully designed to avoid unwanted side effects, as activation or blockade of these receptors can have significant impacts on various physiological processes.

Neuroleptic Malignant Syndrome (NMS) is a rare but potentially life-threatening condition characterized by a group of symptoms that may occur together in individuals taking antipsychotic medications, or in some cases, after the abrupt discontinuation of dopamine agonists.

The four primary features of NMS are:

1. High fever (temperature greater than 38°C/100.4°F)
2. Muscle rigidity or stiffness
3. Altered mental status, which can range from confusion and agitation to a coma
4. Autonomic instability, which can cause symptoms such as irregular pulse or blood pressure, rapid heartbeat, sweating, and unstable body temperature.

Other possible symptoms of NMS may include:

- Tremors or involuntary movements (dyskinesias)
- Labored breathing (dyspnea)
- Changes in heart rate and rhythm (arrhythmias)
- Elevated white blood cell count (leukocytosis)
- Metabolic abnormalities, such as increased creatine phosphokinase levels, elevated liver enzymes, and myoglobinuria.

NMS is a medical emergency that requires immediate treatment, typically involving the discontinuation of the offending medication, supportive care (such as hydration, temperature control, and management of autonomic instability), and sometimes medications to reduce muscle rigidity and lower fever. The exact cause of NMS remains unclear, but it is thought to be related to a dysregulation in dopamine receptors in the brain.

Psychotropic drugs, also known as psychoactive drugs, are a class of medications that affect the function of the central nervous system, leading to changes in consciousness, perception, mood, cognition, or behavior. These drugs work by altering the chemical neurotransmitters in the brain, such as dopamine, serotonin, and norepinephrine, which are involved in regulating mood, thought, and behavior.

Psychotropic drugs can be classified into several categories based on their primary therapeutic effects, including:

1. Antipsychotic drugs: These medications are used to treat psychosis, schizophrenia, and other related disorders. They work by blocking dopamine receptors in the brain, which helps reduce hallucinations, delusions, and disordered thinking.
2. Antidepressant drugs: These medications are used to treat depression, anxiety disorders, and some chronic pain conditions. They work by increasing the availability of neurotransmitters such as serotonin, norepinephrine, or dopamine in the brain, which helps improve mood and reduce anxiety.
3. Mood stabilizers: These medications are used to treat bipolar disorder and other mood disorders. They help regulate the ups and downs of mood swings and can also be used as adjunctive treatment for depression and anxiety.
4. Anxiolytic drugs: Also known as anti-anxiety medications, these drugs are used to treat anxiety disorders, panic attacks, and insomnia. They work by reducing the activity of neurotransmitters such as GABA, which can help reduce anxiety and promote relaxation.
5. Stimulant drugs: These medications are used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. They work by increasing the availability of dopamine and norepinephrine in the brain, which helps improve focus, concentration, and alertness.

It is important to note that psychotropic drugs can have significant side effects and should only be used under the close supervision of a qualified healthcare provider.

Neurotensin is a neuropeptide that is widely distributed in the central nervous system and the gastrointestinal tract. It is composed of 13 amino acids and plays a role as a neurotransmitter or neuromodulator in various physiological functions, including pain regulation, temperature regulation, and feeding behavior. Neurotensin also has been shown to have potential roles in the development of certain diseases such as cancer and neurological disorders. It exerts its effects by binding to specific receptors, known as neurotensin receptors (NTSR1, NTSR2, and NTSR3), which are widely distributed throughout the body.

Harbert CA, Welch MW (1 September 1974). "Antipsychotic and Antianxiety Agents". In Henzelmann RV, Gordon M (eds.). Annual ...
Katzung, BG; Kruidering-Hall, M; Trevor, AJ (eds.). "Chapter 29: Antipsychotic Agents & Lithium". Katzung & Trevor's ... in an oral antipsychotic regimen or 3 months for long-acting injectable antipsychotics 2. Tolerance to antipsychotic effects ( ... which should occur when antipsychotics are withdrawn, and improve or disappear when antipsychotics are restarted) It may ... The antagonizing or "blockade" of D2 by antipsychotics may cause neurons, a type of cell within the brain, to undergo ...
"Evaluation of a new antipsychotic agent. Butaperazine maleate (repoise maleate)". JAMA. 206 (10): 2307-8. December 1968. doi: ... Typical antipsychotic Phenothiazine Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, ... Butaperazine (Repoise, Tyrylen) is a typical antipsychotic of the phenothiazine class. It was approved in 1967, and possibly ... Typical antipsychotics, Propyl compounds, All stub articles, Nervous system drug stubs). ...
de Paulis T (1983). "3. Antipsychotic Agents and Dopamine Agonists". Annual Reports in Medicinal Chemistry. Academic Press. p. ... Flumezapine is an antipsychotic, due to its antagonism of dopamine receptors in the brain. However, like other antipsychotics, ... Flumezapine is structurally related to the common antipsychotic olanzapine-a point that was used against its manufacturer, Eli ... Flumezapine is an abandoned, investigational antipsychotic drug that was studied for the treatment of schizophrenia. ...
Related early antipsychotic agents include declenperone and milenperone. Lenperone was never approved by the FDA for use in ... Butyrophenone antipsychotics, Fluoroarenes, Piperidines, Typical antipsychotics, Veterinary drugs, All stub articles, Nervous ... Lenperone (Elanone-V) is a typical antipsychotic of the butyrophenone chemical class. It was first reported as an anti-emetic ... Table 1. Marketed butyrophenones with approval status and indication Booth NJ (1982). "Psychotropic Agents". In Booth NH, ...
Frankenburg FR, Baldessarini RJ (2008). "Neurosyphilis, malaria, and the discovery of antipsychotic agents". Harv Rev ... doi:10.1001/jama.1901.52470070017001f. Sutter PS (2007). "Nature's agents or agents of empire? Entomological workers and ... 1881). "El mosquito hipotéticamente considerado como agent de transmision de la fiebre amarilla". Anales de la Real Academia de ... Antimicrob Agents Chemother. 50 (6): 1927-30. doi:10.1128/AAC.01472-05. PMC 1479118. PMID 16723547. Weiyuan C (2009). "Ancient ...
March 1994). "Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors ... January 2002). "Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, ... Ganellin CR, Triggle DJ, Macdonald F (1997). Dictionary of pharmacological agents. CRC Press. p. 500. ISBN 978-0-412-46630-4. ... December 2005). "Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the ...
Tohen, Mauricio; Vieta, Eduard (2009). "Antipsychotic agents in the treatment of bipolar mania". Bipolar Disorders. 11 (s2): 45 ... The use of antipsychotic agents in the treatment of acute mania was reviewed by Tohen and Vieta in 2009. When the manic ... Various lines of evidence from post-mortem studies and the putative mechanisms of anti-manic agents point to abnormalities in ... Other medications possibly include glutaminergic agents and drugs that alter the HPA axis. Lifestyle triggers include irregular ...
Haloperidol, an antipsychotic medication, was a preferred agent. See Diagnosis.[circular reference] Furthermore, patients were ... page needed] Another antipsychotic medication, chlorpromazine (trade name Thorazine™), was also used to induce grogginess, ... "Haloperidol: Antipsychotic Medication Used Frequently in Iranian Prisons". iranwire.com. Retrieved 2022-12-01. Rejali 2009, p. ... as part of a 1950s secret program run by the US army that tested chemical warfare agents on US citizens. A few cases of ...
Morin AK (March 2014). "Off-label use of atypical antipsychotic agents for treatment of insomnia". Mental Health Clinician. 4 ( ... August 2008). "Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4- ... January 1997). "Disposition and biotransformation of the antipsychotic agent olanzapine in humans". Drug Metabolism and ... which is a common property of most atypical antipsychotics, aside from the benzamide antipsychotics such as amisulpride along ...
So cotreatment with another, more potent, antipsychotic agent is needed. Chlorprothixene is structurally related to ... "Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors". J. ... antipsychotic effects, sedation/anxiolysis, antidepressant effect, weight gain D1, D2, D3, D4, D5: antipsychotic effects, ... Also, like most antipsychotics, chlorprothixene has antiemetic effects. Chlorprothixene has a strong sedative activity with a ...
Davidson AB, Boff E, MacNeil DA, Wenger J, Cook L (1983). "Pharmacological effects of Ro 22-1319: a new antipsychotic agent". ... Piquindone (Ro 22-1319) is an atypical antipsychotic with a tricyclic structure that was developed in the 1980s but was never ... isoquinoline antipsychotics". Journal of Medicinal Chemistry. 24 (9): 1026-34. doi:10.1021/jm00141a002. PMID 6116805. ... "Structural requirements of Na+-dependent antidopaminergic agents: Tropapride, Piquindone, Zetidoline, and Metoclopramide. ...
532-. ISBN 978-0-19-162675-3. Psychotropic Agents: Part I: Antipsychotics and Antidepressants. Springer Science & Business ... 836-. ISBN 978-0-7817-2845-4. Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties ...
396-. ISBN 978-94-011-5913-5. Psychotropic Agents: Part I: Antipsychotics and Antidepressants. Springer Science & Business ... Prothipendyl is said to not possess antipsychotic effects, and in accordance, appears to be a weaker dopamine receptor ...
Psychotropic Agents: Part I: Antipsychotics and Antidepressants. Springer Science & Business Media. 2012-12-06. ISBN ... Pipamperone is considered to have been a forerunner to the atypical antipsychotics, if not an atypical antipsychotic itself, ... Prinssen EP, Koek W, Kleven MS (January 2000). "The effects of antipsychotics with 5-HT(2C) receptor affinity in behavioral ... 88-. ISBN 978-1-4200-4177-4. Awouters FH, Lewi PJ (2007). "Forty years of antipsychotic Drug research--from haloperidol to ...
... the potential impact of antipsychotic agents". Psychoneuroendocrinology. 28: 97-108. doi:10.1016/S0306-4530(02)00129-4. ISSN ...
Morin AK (1 March 2014). "Off-label use of atypical antipsychotic agents for treatment of insomnia". Mental Health Clinician. 4 ... However, while common, use of antipsychotics for this indication is not recommended as the evidence does not demonstrate a ... Thompson W, Quay TA, Rojas-Fernandez C, Farrell B, Bjerre LM (June 2016). "Atypical antipsychotics for insomnia: a systematic ... Yoshida K, Takeuchi H (March 2021). "Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia ...
September 1991). "The effects of umespirone as a potential anxiolytic and antipsychotic agent". Pharmacology Biochemistry and ... As a result, further development has commenced to bring more selective of anxiolytic agents to the market. An example of this ... Kato T, Hirose A, Ohno Y, Shimizu H, Tanaka H, Nakamura M (December 1990). "Binding profile of SM-9018, a novel antipsychotic ... Azapirones are a class of drugs used as anxiolytics, antidepressants, and antipsychotics. They are commonly used as add-ons to ...
... the potential impact of antipsychotic agents". Psychoneuroendocrinology. 28 (Suppl 2): 97-108. doi:10.1016/s0306-4530(02)00129- ... Typical antipsychotics have been shown to induce significant, dose-dependent increases in prolactin levels up to 10-fold the ... Particularly, antipsychotics have been linked to a majority of non-tumor related hyperprolactinemia cases due to their ... Atypical antipsychotics vary in their ability to elevate prolactin levels, however, medications in this class such as ...
September 1991). "The effects of umespirone as a potential anxiolytic and antipsychotic agent". Pharmacology Biochemistry and ... Krähling H, Fuchs A, Ruhland M, Schön U, Mol F, Tulp M (November 1988). "KC 9172 (free base of KC 7218)--an antipsychotic/ ... Umespirone (KC-9172) is a drug of the azapirone class which possesses anxiolytic and antipsychotic properties. It behaves as a ... Ruhland M, Krähling H, Fuchs A, Schön U (November 1988). "KC 9172 (free base of KC 7218)--an antipsychotic/anxiolytic compound ...
Other medications can be added to SSRIs if a partial response is achieved and further improvement is needed; these agents ... antipsychotics, anti‐attention‐deficit/hyperactivity medications and mood stabilizers in children and adolescents with ... include lithium, bupropion and atypical antipsychotics. These options are medications that work in different ways. Bupropion ( ...
"Enhancement of drug withdrawal convulsion by combinations of phenobarbital and antipsychotic agents". Japanese Journal of ... Antipsychotics increase the severity of benzodiazepine withdrawal effects with an increase in the intensity and severity of ... phenothiazines and other antipsychotics, skeletal muscle relaxants, antihistamines, and anaesthetics. Administration of ...
"Antibacterial property of the antipsychotic agent prochlorperazine, and its synergism with methdilazine". Microbiol Res. 160 (1 ... The ring-contracted analog, methdilazine shows only very weak activity as a tranquilizer; instead, that agent constitutes an ... "Antimicrobial properties of methdilazine and its synergism with antibiotics and some chemotherapeutic agents". ...
An antipsychotic agent BMS 181100 is synthesized using BINAP/diamine-Ru catalyst. Midland Alpine Borane Reduction Corey-Itsuno ... and the antipsychotic agent BMS181100. The stoichiometric asymmetric reduction of ketones has long been known, e.g., using ...
... a new type of antipsychotic agent?". Progress in Medicinal Chemistry. 33: 185-232. doi:10.1016/s0079-6468(08)70306-0. ISBN ... Barnes TR (22 October 2013). Antipsychotic Drugs and Their Side-Effects. Elsevier Science. pp. 28, 34. ISBN 978-1-4832-8810-9. ... is said to be ineffective as an antipsychotic. However, it retains higher affinity for the dopamine D1 receptor (IC50 = 198 nM ...
"Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents". Journal of Clinical ... Other uses include treatment of obesity, binge eating disorder, and off-setting weight gain induced by taking antipsychotic ...
Some antipsychotic agents may be riskier than others during withdrawal, especially clozapine, olanzapine or low potency ... Antipsychotics are generally ineffective for benzodiazepine withdrawal-related psychosis. Antipsychotics should be avoided ... "Enhancement of drug withdrawal convulsion by combinations of phenobarbital and antipsychotic agents". The Japanese Journal of ... Bobolakis, Ioannis (2000). "Neuroleptic Malignant Syndrome After Antipsychotic Drug Administration During Benzodiazepine ...
Roix JJ, DeCrescenzo GA, Cheung PH, Ciallella JR, Sulpice T, Saha S, Halse R (April 2012). "Effect of the antipsychotic agent ... The mainstay of treatment for schizophrenia is an antipsychotic medication. Most antipsychotics can take around 7 to 14 days to ... the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine". BMJ Open. 4 (3 ... Most people on antipsychotics get side effects. People on typical antipsychotics tend to have a higher rate of extrapyramidal ...
"Safety and tolerability of antipsychotic agents in neurodevelopmental disorders: a systematic review". Expert Opin Drug Saf ( ... The antihypertensive agents are also used to treat tics; studies show variable efficacy, but a lower side effect profile than ... The traditional antipsychotic drugs are associated with tardive dyskinesia when used long-term; and parkinsonism, dystonia, ... Neuroleptic medications (antipsychotics), such as haloperidol (brand name Haldol) or pimozide (brand name Orap), have ...
"Inhibition of human alpha1E subunit-mediated ca2+ channels by the antipsychotic agent chlorpromazine". Acta Physiologica ...
The antipsychotic medications are invaluable adjuncts to the treatment of psychosis and bipolar illness and have revolutio … ... conventional agents. They are also referred to as first and second generation antipsychotic agents. ... Antipsychotic Agents Review. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda ... The antipsychotic agents in clinical use include the phenothiazines and structurally similar compounds such as thioxanthenes, ...
Antipsychotic agents. Class Summary. These agents may improve choreic movements in patients. ... Depression in patients with HD can be treated with the same agents used for treatment of depression of any other cause. SSRIs ... Carboxylic acid commonly used as antiepileptic drug, mood stabilizer in mania, and prophylactic agent for migraine. When ... Therapeutic options include dopamine-depleting agents (eg, reserpine, tetrabenazine, valbenazine) and dopamine-receptor ...
Atypical antipsychotics. Class Summary. These agents provide a number of major improvements over the traditional agents, ... Antipsychotics. Class Summary. High-potency classic agents (eg, haloperidol) provide rapid, predictable, and effective sedation ... High-potency antipsychotics are recommended for rapid tranquilization; lower-potency antipsychotics (eg, chlorpromazine) might ... Antialcoholic agents. Class Summary. A patient who is highly motivated to participate in an abstinence program may benefit from ...
The Routine Use of Atypical Antipsychotic Agents: Maintenance Treatment. Bruce J. Kinon, M.D. ... Although data are scarce formaintenance treatment with atypical antipsychotic drugs, findings suggest that atypical agents are ... Placebo-controlled maintenance studies of conventional antipsychotic agents demonstrate a significantreduction in the risk of ...
... and other atypical antipsychotic drugs (APDs) have fewer extrapyramidal side effects, they have serious metabolic side effects ... Antipsychotic Agents / adverse effects * Antipsychotic Agents / pharmacology* * Antipsychotic Agents / therapeutic use * ... Effects of antipsychotic medications on appetite, weight, and insulin resistance Endocrinol Metab Clin North Am. 2013 Sep;42(3 ... 1 Antipsychotic Research Laboratory, School of Health Sciences, Illawarra Health and Medical Research Institute, University of ...
Antipsychotic Agents. Class Summary. Chorea, tics, and other adventitious movements such as oral dyskinesia may respond to ... Agents such as the atypical antipsychotics for chorea and anti-Parkinson disease drugs for patients with NA and Parkinson ... An agent that can decrease anxiety, such as a benzodiazepine, can also decrease movement disorders often made worse by ... particularly because compliance and swallowing problems may lead to undesired daily variations of the dopamine blocking agent ...
Clinical decision support for Atypical Antipsychotic Agents. Treatment and management. Indications, Mechanism of Action, ... Atypical Antipsychotic Agents. Author: Contributor Profile. Practicing Physician Mountain Top. Disclosure. Keith Willner, MD, ... Many second-generation antipsychotics also cause significant sedation by antihistamine activity; these agents are aripiprazole ... Over the past two decades, many novel antipsychotic agents have undergone development, but so far, there is little solid ...
... a low-potency agent) Haloperidol (a high-potency agent) Atypical Antipsychotic Clozapine Three Types of Symptoms Symptoms of ... Antipsychotic Agents and Their Use in Schizophrenia. Published on 08/04/2017 by admin ... The phenothiazines were the first modern antipsychotic agents. Chlorpromazine, our prototype of the low-potency neuroleptics, ... Schizophrenia is the primary indication for antipsychotic drugs. These agents effectively suppress symptoms during acute ...
Task Force on Late Neurological Effects of Antipsychotic Drugs.. Series: Task force report ; 18Material type: Text; Format: ... Tardive dyskinesia : report of the American Psychiatric Association Task Force on Late Neurological Effects of Antipsychotic ...
Antipsychotic Agents ByT. H. Corn, J. R. M. Haigh. Abstract part VIII. ,. 37 pages. Assessment of Drug Effects on the ...
Antipsychotics And Antianxiety Agents. The concomitant administration of RYANODEX with antipsychotic and antianxiety agents may ... Avoid agents that trigger MH.. If surgery is prolonged, administer additional individualized RYANODEX doses during anesthesia ... When reconstituted with 5 mL sterile water for injection USP (without a bacteriostatic agent), this yields a suspension with a ... Ryanodex may interact with calcium channel blockers, muscle relaxants, and antipsychotic and antianxiety drugs. Tell your ...
TopRx is a nationally recognized pharmacy supplies distributor committed to serving independent pharmacies and other healthcare facilities through outstanding customer service. Order today!
Harbert CA, Welch MW (1 September 1974). "Antipsychotic and Antianxiety Agents". In Henzelmann RV, Gordon M (eds.). Annual ...
Antipsychotic Agents. Phenothiazines. Disclaimer: Information presented in this database is not meant as a substitute for ...
Antipsychotic medications can treat dementia symptoms such as aggression or psychosis. But these drugs can cause serious side ... Doctors prescribe atypical antipsychotics more often than typical antipsychotic agents due to their reduced risk of side ... However, typical antipsychotics may not be the best antipsychotics for older adults with dementia because of the risk of side ... Typical antipsychotics include:. *Haloperidol (Haldol): The most common prescription typical antipsychotic for dementia. This ...
... as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents. In: Journal of medicinal ... as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents. Journal of medicinal ... as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents, Journal of medicinal ... as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents. Journal of medicinal ...
c involuntary medication with injectable antipsychotic agents. * d group therapy. * e anxiolytics. ... then it might be reasonable to try an antipsychotic medication (Reference Grossman and MagnavitaGrossman 2004). However, no ...
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.. ...
NOVEL PEPTIDE-BASED NANOVESICULAR FORMULATION OF AN ANTIPSYCHOTIC AGENT FOR TRANSDERMAL DELIVERY. *At: AbuDhabi (United Arab ... Asenapine maleate (ASP) is an atypical antipsychotic used clinically in the treatment of schizophrena and bipolar disorder. It ...
Pharmacology of Antipsychotic Agents Cheat Sheet. kfisher17. 24 Feb 20. of, drugs, symptoms, neurotransmitters, dementia and 19 ...
Organic Compound; Amine; Drug; Food Toxin; Antipsychotic Agent; Antiemetic; Serotonin Uptake Inhibitor; Metabolite; Synthetic ... Atypical antipsychotic. Displays anticholinergic properties. Tocris Bioscience 4349. ... Atypical antipsychotic. Displays anticholinergic properties. Tocris Bioscience 4349. ... Atypical antipsychotic. Displays anticholinergic properties. Tocris Bioscience 4349. ...
Pharmacological Actions : Antipsychotic Agents. [+] Cannabidiol may have therapeutic value as an antipsychotic drug. Apr 01, ... This review further confirms the potential of CBD as an effective, safe and well tolerated antipsychotic compound.Feb 28, 2015 ... Kratom leaf extract exhibits antipsychotic-like effect with the potential to alleviate positive and negative symptoms of ...
Pharmacological Actions : Antipsychotic Agents. Problem Substances : Amphetamine. [+] A variety of drugs may contribute to ... Asiatic acid is a promising candidate for an anti-neurotoxic agent.Dec 10, 2017. ...
Treatment with the antipsychotic agent, risperidone, reduces disease severity in experimental autoimmune encephalomyelitis. ...
Cognitive effects of antipsychotic agents in persons with traumatic brain injury. Brain Inj. 1997 May. 11(5):335-41. [QxMD ... The use of antipsychotics to treat posttraumatic agitation is controversial. Their effects on cognition and recovery are poorly ... The study pointed to the fact that in TBI, a survival advantage can be achieved through the administration of agents, such as ... Zafonte RD, Lexell J, Cullen N. Possible applications for dopaminergic agents following traumatic brain injury: part 2. J Head ...
That included five antipsychotic agents." This patient didnt even have a psychiatric disorder, says Kruszewski. She was ... In her six months at the facility, she suffered a common side effect of antipsychotics: Her weight b allooned from 106 pounds ... Its very bad medicine." A comparable medical result might be achieved with a low dose of Haldol, an older antipsychotic, for ... Consider the so-called atypical antipsychotics, a group of newer, pricey drugs created to suppress serious psychiatric symptoms ...
CI: (c) 2012; JID: 101168070; 0 (Antipsychotic Agents); 2012/05/15 [aheadofprint]; ppublish ... An assessment of periodontal health in patients with schizophrenia and taking antipsychotic medication 2013 Department of ... because of the use of antipsychotic medications in patients with schizophrenia. METHODS: Group A (n=33) included patients who ...
Disruption of body temperature regulation has been attributed to antipsychotic agents. Both hyperthermia and hypothermia have ... Risperidone is associated with higher levels of prolactin elevation than other antipsychotic agents. ... Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs ... events of leukopenia/neutropenia have been reported temporally related to antipsychotic agents, including risperidone. ...
  • The antipsychotic medications are invaluable adjuncts to the treatment of psychosis and bipolar illness and have revolutionized management of these conditions. (nih.gov)
  • The antipsychotic medications are usually classified into conventional and atypical agents, based upon relative risks for extrapyramidal side effects that are greater with the older, conventional agents. (nih.gov)
  • The initial antipsychotic medications introduced into clinical practice were the phenothiazines, but they have been largely replaced in recent years by the atypical agents. (nih.gov)
  • Miscellaneous conventional antipsychotic medications include haloperidol (Haldol: 1967), loxapine (Loxitane: 1976), molindone (Moban: 1974) and pimozide (Orap: 1984, used largely for Tourette syndrome). (nih.gov)
  • Doctors sometimes prescribe antipsychotic medications to treat neuropsychiatric symptoms (NPSs) of dementia, which can include aggression or psychosis. (medicalnewstoday.com)
  • Antipsychotic medications can help manage symptoms of severe mental illness and prevent repeat episodes. (medicalnewstoday.com)
  • There are two main types of antipsychotic medications. (medicalnewstoday.com)
  • In 2005, the Food and Drug Administration (FDA) issued a black box warning regarding the use of antipsychotic medications to treat older adults with dementia. (medicalnewstoday.com)
  • If these medications and behavioral interventions are ineffective, providers may try antipsychotic medications, which may reduce the frequency and intensity of symptoms. (medicalnewstoday.com)
  • Perphenazine is one of the older, first-generation antipsychotic medications. (medicinenet.com)
  • The majority of patients prescribed antipsychotic medications in state Medicaid programs are taking these agents for off-label indications. (ajmc.com)
  • Off-label use of antipsychotic medications is common, particularly among the elderly and children/adolescents. (ajmc.com)
  • This study documented rates of off-label use of antipsychotic medications in 42 state Medicaid programs in 2003. (ajmc.com)
  • Antipsychotic medications have long been an important component of effective treatment for schizophrenia. (ajmc.com)
  • They also make up a large and growing share of Medicaid prescription drug programs, which covered nearly 75% of all prescriptions for antipsychotic medications in the United States in 2002, 1 although since 2006 the public share of financing for antipsychotic medications has been roughly equally divided between Medicaid and Medicare. (ajmc.com)
  • Pooled analysis of two similarly designed 52-week trials has shown aripiprazole to be an effective maintenance treatment for patients undergoing an acute psychotic episode who had previously responded to antipsychotic medications. (medscape.com)
  • Method: The subjects of this study were schizophrenia patients who received oral antipsychotic medications from 1997 to 2007. (go.jp)
  • Antipsychotic medications were reviewed to determine their potential and the cause of substitution in association with khat use. (who.int)
  • Perphenazine (brand name Trilafon is discontinued) is an oral antipsychotic medication used to manage schizophrenia . (medicinenet.com)
  • Continuously enrolled patients with at least 1 prescription for an antipsychotic medication were identified. (ajmc.com)
  • Of the 372,038 individuals given an antipsychotic medication, 214,113 (57.6%) received these agents for off-label disorders. (ajmc.com)
  • In an effort to promote the optimal use of antipsychotic medication, we examined the current state of antipsychotic polypharmacy and the use of excessive doses in outpatients with schizophrenia. (go.jp)
  • Introduction: Sexual dysfunction is common in individuals with psychiatric disorders and under psychotropic medication such as antidepressants and antipsychotics. (kcl.ac.uk)
  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. (nih.gov)
  • A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. (druglib.com)
  • Although clozapine, olanzapine, and other atypical antipsychotic drugs (APDs) have fewer extrapyramidal side effects, they have serious metabolic side effects such as substantial weight gain, intra-abdominal obesity, and type 2 diabetes mellitus. (nih.gov)
  • Second-generation antipsychotics such as risperidone, ziprasidone, paliperidone, and aripiprazole are all potent antagonists of dopamine D2 receptors, while clozapine and quetiapine are weak D2 antagonists. (statpearls.com)
  • Almost all atypical antipsychotics bind to alpha-adrenergic receptors, but the most potent are clozapine, risperidone, iloperidone, and clozapine. (statpearls.com)
  • Quetiapine, clozapine, and olanzapine have high anticholinergic properties, whereas other atypical antipsychotics very weakly bind to muscarinic cholinergic receptors. (statpearls.com)
  • The mean increase in weight over a ten-week period for patients treated with standard doses of atypical antipsychotics was 4.45 kg with clozapine and 4.15 kg with olanzapine. (statpearls.com)
  • Typical antipsychotics (eg, haloperidol) effectively treat psychosis with acute agitation, which is at least partially attributed to their benefit of rapid tranquilization. (medscape.com)
  • High-potency classic agents (eg, haloperidol) provide rapid, predictable, and effective sedation in the management of acutely psychotic patients. (medscape.com)
  • Atypical antipsychotics with D2 antagonism and partial agonism combined with 5HT2A antagonism have greater efficacy for mania, and these include aripiprazole, quetiapine, olanzapine, risperidone, and asenapine. (statpearls.com)
  • [ 32 ] Consistent with published trial results, a recent Cochrane review of clinical data noted that aripiprazole has comparable antipsychotic efficacy to conventional and other atypical antipsychotics for the treatment of schizophrenia. (medscape.com)
  • Among atypical antipsychotics, olanzapine can be provided in both oral and intramuscular forms and is also effective in treating psychosis with acute agitation. (medscape.com)
  • If psychosis persists beyond elimination of the offending substance, an atypical antipsychotic drug (eg, risperidone, olanzapine, quetiapine) may be considered. (medscape.com)
  • The title compound, generic name olanzapine, is one of the newer generation atypical antipsychotic agents. (iucr.org)
  • Placebo-controlled maintenance studies of conventional antipsychotic agents demonstrate a significantreduction in the risk of schizophrenic relapse in neuroleptic-treated patients. (psychiatrist.com)
  • They are "atypical" as they are differentiated from "conventional" or first-generation antipsychotics based on their clinical profile. (statpearls.com)
  • Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. (druglib.com)
  • Phenothiazines in current use (with initial brand names and date of first approval) include chlorpromazine (Thorazine: 1957, the initial prototype antipsychotic agent), fluphenazine (Prolixin: 1972), perphenazine (Trilafon: 1957), prochlorperazine (Compazine: 1956, used mostly as therapy of nausea rather than psychosis), thioridazine (Mellaril: 1978), and trifluoperazine (Stelazine: 1959). (nih.gov)
  • lower-potency antipsychotics (eg, chlorpromazine) might require higher doses. (medscape.com)
  • Khat use hinders an individual's response to initial antipsychotic drug treatment for schizophrenia. (who.int)
  • To determine how often antipsychotics are prescribed off-label to adults without schizophrenia or bipolar disorder who are enrolled in Medicaid, which pays for more than 70% of antipsychotic prescriptions in the United States. (ajmc.com)
  • 57.6% of patients given an antipsychotic had no diagnoses of schizophrenia or bipolar disorder during the year. (ajmc.com)
  • The antipsychotic agents in clinical use include the phenothiazines and structurally similar compounds such as thioxanthenes, benazepines, butyrophenones, diphenylbutylpiperidines and miscellaneous similar heterocyclic compounds. (nih.gov)
  • Thus, they should be considered second-line agents and only after hemodynamic stability and risks of alcohol withdrawal have been addressed with benzodiazepines. (medscape.com)
  • Antihistamines Antipsychotic Agents, Benzodiazepines. (pediatriconcall.com)
  • Although data are scarce formaintenance treatment with atypical antipsychotic drugs, findings suggest that atypical agents are atleast as efficacious and may be better tolerated. (psychiatrist.com)
  • Agents such as the atypical antipsychotics for chorea and anti-Parkinson disease drugs for patients with NA and Parkinson disease features may be of value. (medscape.com)
  • In recent years, atypical antipsychotics or second-generation antipsychotics have become the drugs of choice for acute psychoses. (statpearls.com)
  • Maintenance therapy with antipsychotic drugs reduces the risk for acute relapse but may fail to prevent long-term deterioration. (clinicalgate.com)
  • Tardive dyskinesia : report of the American Psychiatric Association Task Force on Late Neurological Effects of Antipsychotic Drugs. (who.int)
  • Task Force on Late Neurological Effects of Antipsychotic Drugs. (who.int)
  • Ryanodex may interact with calcium channel blockers, muscle relaxants, and antipsychotic and antianxiety drugs. (rxlist.com)
  • This article explains what antipsychotic drugs are and which can help treat dementia. (medicalnewstoday.com)
  • What are antipsychotic drugs? (medicalnewstoday.com)
  • Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/ cerebrovascular risk. (nih.gov)
  • Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. (druglib.com)
  • A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs. (druglib.com)
  • The risk of developing tardive dyskinesia and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. (druglib.com)
  • They are less sedating and are more easily titrated but are more likely to cause extrapyramidal adverse effects than the lower-potency agents. (medscape.com)
  • They have fewer side effects regarding extrapyramidal symptoms when compared to typical antipsychotics. (statpearls.com)
  • Neonates exposed to antipsychotics during the third trimester of pregnancy are at risk for extrapyramidal and withdrawal symptoms after birth. (medicinenet.com)
  • As with all antipsychotic agents, tardive dyskinesia may appear in some patients on long-term therapy or may appear after drug therapy has been discontinued. (medicinenet.com)
  • Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown. (druglib.com)
  • Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (bvsalud.org)
  • Atypical antipsychotics have transformed the treatment of psychoses as they are prescribed for acute psychoses and in the management of schizophrenia, affective disorders (depression and mania), and geriatric agitation. (statpearls.com)
  • Doctors can legally prescribe antipsychotics off-label to treat serious dementia symptoms, such as hallucinations and agitation. (medicalnewstoday.com)
  • Among the 527 patients on monotherapy, 53.5% were prescribed first-generation antipsychotics (FGAs) and 46.5% were prescribed second-generation antipsychotics (SGAs) in the period from 1997 through 2007. (go.jp)
  • Patients with newly diagnosed schizophrenia on antipsychotic monotherapy ( n = 1007, 817 men) were included and categorized into khat and non-khat users. (who.int)
  • Depot antipsychotics are not intended for use in the acute setting. (medscape.com)
  • Antipsychotics also have histamine, muscarinic (cholinergic), and alpha-adrenergic antagonism. (statpearls.com)
  • Purpose: Antipsychotic polypharmacy has been utilized frequently in the clinical setting despite lack of evidence for its safety or efficacy. (go.jp)
  • Lithium is also frequently discussed in the context of antipsychotic therapies, although its major use is for stabilization of bipolar illness. (nih.gov)
  • Asenapine maleate (ASP) is an atypical antipsychotic used clinically in the treatment of schizophrena and bipolar disorder. (fip.org)
  • No single atypical antipsychotic drug has been proven most beneficial for treatment of persistent alcohol-related psychosis. (medscape.com)
  • In greater doses it's an anti- hallucinogenic agent. (bionity.com)
  • A lithium salt, classified as a mood-stabilizing agent. (curehunter.com)
  • Although the exact mechanism of antipsychotics is unknown, scientists believe they may work by blocking the action of dopamine in the brain. (medicinenet.com)
  • The second generation, or atypical antipsychotics, are dopamine antagonists that block serotonin receptors and affect serotonin levels. (medicalnewstoday.com)
  • Reducing off-label antipsychotic use may generate savings with little impact on patient outcomes. (ajmc.com)
  • Greater awareness among psychiatrists at Nagoya University Hospital of the proper use of antipsychotics has resulted in a reduced prevalence of antipsychotic polypharmacy and less frequent use of excessive dosages. (go.jp)
  • Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. (druglib.com)
  • The first generation, or typical antipsychotics, are dopamine receptor blockers that work by blocking dopamine receptors in the brain. (medicalnewstoday.com)
  • Perphenazine is used when patients do not respond to other antipsychotics. (medicinenet.com)
  • First-generation antipsychotics can be classified as low potency, medium potency, or high potency ( Table 24.2 ). (clinicalgate.com)
  • Treatment with second-generation antipsychotics can contribute to weight gain and, subsequently, metabolic syndrome with high blood sugar, hypertension, abnormal cholesterol, and triglyceride concentrations, posing a patient at risk for stroke, myocardial disease, and diabetes mellitus. (statpearls.com)
  • Trifluoperazine (sold as Eskazinyl , Eskazine , Jatroneural , Modalina , Stelazine , Terfluzine , Trifluoperaz ) is a typical antipsychotic drug of the phenothiazine group. (bionity.com)
  • However, typical antipsychotics may not be the best antipsychotics for older adults with dementia because of the risk of side effects. (medicalnewstoday.com)
  • The most common prescription typical antipsychotic for dementia. (medicalnewstoday.com)
  • Doctors prescribe atypical antipsychotics more often than typical antipsychotic agents due to their reduced risk of side effects. (medicalnewstoday.com)
  • Carboxylic acid commonly used as antiepileptic drug, mood stabilizer in mania, and prophylactic agent for migraine. (medscape.com)
  • ADMET studies coupled with a behavioral test using the amphetamine-induced hyperactivity model identified four compounds possessing drug-like profiles and having antipsychotic properties. (johnshopkins.edu)
  • In Vivo Phenotypic Drug Discovery: Applying a Behavioral Assay to the Discovery and Optimization of Novel Antipsychotic Agents. (psychogenics.com)
  • Results: Sixty-four percent of patients on antipsychotic pharmacotherapy received a single antipsychotic drug, and 36% received two or more. (go.jp)
  • The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. (druglib.com)
  • If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. (druglib.com)
  • Although and response to antipsychotic treatment in schizophrenia limited use may not be accompanied by serious conse- patients. (who.int)
  • They are also referred to as first and second generation antipsychotic agents. (nih.gov)
  • Learn more about second-generation antipsychotics. (medicalnewstoday.com)
  • And because these people are usually quite disabled from their psychiatric condition, they often are taking modern antipsychotic agents that affect diabetes management. (medscape.com)
  • Une recherche documentaire a été effectuée dans PubMed de 1980 à 2021 en utilisant diverses combinaisons de termes MeSH comme tabac, diabète, hypertension, dyslipidémie, trouble dépressif majeur, trouble bipolaire, schizophrénie. (who.int)
  • Rhabdomyolysis and the neuroleptic malignant syndrome are always concerns in patients with NA, particularly because compliance and swallowing problems may lead to undesired daily variations of the dopamine blocking agent blood levels. (medscape.com)
  • Undesirable alterations have been observed in patients treated with atypical antipsychotics. (nih.gov)
  • BACKGROUND: The possibility of atypical antipsychotics (AA) to induce manic symptoms has been raised by several articles. (mcmaster.ca)
  • Thus, it is the lab work or a history that includes use of anti-hyperglycemic agents that selects out the endocrinologist as the non-psychiatrist responsible for periodic rounds and the need to address some of those unrelated review-of-systems symptoms, because this endocrinologist is often the only consultant. (medscape.com)
  • These agents are used to manage muscle spasms in chorea. (medscape.com)